Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How did I get my own unique set of fingerprints? - 2New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
- 3Virtual reality opens doors for older people to build closer connections in real life
- 4Figure out How to Amplify the Resale Worth of Your Kona SUV
- 5The top astronomical discoveries of 2025
- Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- Step by step instructions to Think about Disc Rates Across Various Banks
- New movies to watch this weekend: See 'The Running Man' in theaters, rent 'One Battle After Another,' stream 'Nobody 2' on Peacock
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- Supportive Tips On Home loans For First-Time Home Purchasers
- Weight-loss pill approval set to accelerate food industry product overhauls
- Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
